Cencora (COR) – Investment Analysts’ Recent Ratings Updates

Cencora (NYSE: COR) recently received a number of ratings updates from brokerages and research firms:

• 10/30/2026 – Cencora had its price target raised by Morgan Stanley from $346.00 to $377.00. They now have an “overweight” rating on the stock.
• 10/22/2026 – Cencora had its price target raised by Robert W. Baird from $373.00 to $375.00. They now have an “outperform” rating on the stock.
• 10/20/2026 – Cencora had its price target raised by Argus from $340.00 to $380.00. They now have a “buy” rating on the stock.
• 10/16/2026 – Cencora had its price target lowered by UBS Group from $430.00 to $400.00. They now have a “buy” rating on the stock.
• 10/12/2026 – Cencora had its price target raised by Robert W. Baird from $370.00 to $373.00. They now have an “outperform” rating on the stock.
• 10/7/2026 – Cencora had its price target raised by Leerink Partners from $380.00 to $388.00. They now have an “outperform” rating on the stock.
• 10/6/2026 – Cencora was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 9/8/2026 – Cencora had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $330.00 price target on the stock.

Cencora Trading Up 3.7%

NYSE COR traded up $12.54 on Wednesday, hitting $353.04. 1,121,734 shares of the stock were exchanged, compared to its average volume of 1,459,345. The company’s 50-day moving average price is $324.08 and its two-hundred day moving average price is $317.45. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.58. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54. The company has a market capitalization of $67.37 billion, a price-to-earnings ratio of 26.23, a P/E/G ratio of 1.73 and a beta of 0.58.

Cencora (NYSE:COR) last released its earnings results on Wednesday, November 4th. The company reported $4.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.58 by $0.08. The company had revenue of $88.35 billion during the quarter, compared to analyst estimates of $87.95 billion. Cencora had a return on equity of 125.45% and a net margin of 0.79%. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.84 earnings per share. Research analysts predict that Cencora, Inc. will post 17.88 EPS for the current year.

Insider Activity

In related news, EVP Elizabeth Campbell sold 11,300 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares in the company, valued at approximately $6,305,754.60. This trade represents a 36.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.38% of the stock is owned by company insiders.

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.